MOBOCERTINIB for Lung neoplasm malignant: Side Effects & Safety Data
Boost Your Natural Energy & Metabolism
Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.
There are 291 adverse event reports in the FDA FAERS database where MOBOCERTINIB was used for Lung neoplasm malignant.
Most Reported Side Effects for MOBOCERTINIB
| Side Effect | Reports | % | Deaths | Hosp. |
|---|---|---|---|---|
| Diarrhoea | 309 | 43.2% | 88 | 133 |
| Death | 160 | 22.4% | 160 | 40 |
| Rash | 106 | 14.8% | 20 | 37 |
| Non-small cell lung cancer | 96 | 13.4% | 43 | 21 |
| Nausea | 85 | 11.9% | 19 | 39 |
| Decreased appetite | 80 | 11.2% | 27 | 36 |
| Lung neoplasm malignant | 74 | 10.4% | 32 | 14 |
| Vomiting | 74 | 10.4% | 29 | 47 |
| Fatigue | 66 | 9.2% | 17 | 32 |
| Asthenia | 56 | 7.8% | 22 | 33 |
| Weight decreased | 54 | 7.6% | 9 | 21 |
| Dry skin | 52 | 7.3% | 7 | 17 |
| Stomatitis | 45 | 6.3% | 8 | 19 |
| Pneumonia | 44 | 6.2% | 20 | 35 |
| Product dose omission issue | 42 | 5.9% | 11 | 24 |
Other Indications for MOBOCERTINIB
Product used for unknown indication (170)
Non-small cell lung cancer (169)
Lung adenocarcinoma (29)
Egfr gene mutation (26)
Non-small cell lung cancer metastatic (14)
Lung carcinoma cell type unspecified stage iv (12)
Lung cancer metastatic (10)
Lung adenocarcinoma stage iv (9)
Non-small cell lung cancer stage iv (9)
Bone cancer (8)
Other Drugs Used for Lung neoplasm malignant
ERLOTINIB (9,207)
OSIMERTINIB (4,754)
NIVOLUMAB (4,197)
PEMBROLIZUMAB (3,575)
CARBOPLATIN (3,487)
ALECTINIB (2,932)
PEMETREXED (2,422)
CRIZOTINIB (1,949)
BEVACIZUMAB (1,810)
PACLITAXEL (1,747)